niacinamide has been researched along with Epithelial Neoplasms in 9 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-125 levels after maximal surgical cytoreduction were randomized (1:1) to receive treatment with paclitaxel (175 mg/m(2) , 3 h infusion, day 1) and carboplatin (AUC 6." | 6.80 | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. ( Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC, 2015) |
| "Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle." | 6.76 | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. ( Bodnar, L; Górnas, M; Szczylik, C, 2011) |
| "Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-125 levels after maximal surgical cytoreduction were randomized (1:1) to receive treatment with paclitaxel (175 mg/m(2) , 3 h infusion, day 1) and carboplatin (AUC 6." | 2.80 | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. ( Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC, 2015) |
| "This study was designed to evaluate the response and toxicity of sorafenib alone or when combined with carboplatin and paclitaxel in patients with platinum-sensitive, recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (EOC)." | 2.79 | Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. ( Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ, 2014) |
| "Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle." | 2.76 | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. ( Bodnar, L; Górnas, M; Szczylik, C, 2011) |
| "Sorafenib is a novel oral anticancer agent targeting signal transduction and angiogenic pathways through inhibitory effects against MAP kinases and vascular endothelial growth factor receptor-2." | 2.75 | Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. ( Coch, C; Eckhardt, M; Hartmann, G; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Wolfgarten, M, 2010) |
| "Intermittent sorafenib dosing with bevacizumab has promising clinical activity and less sorafenib dose reduction and side effects, but does not ameliorate HFSR." | 1.36 | Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. ( Annunziata, CM; Azad, N; Houston, N; Kohn, EC; Kotz, H; Lee, JM; Minasian, L; Sarosy, GA; Squires, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwandt, A | 1 |
| von Gruenigen, VE | 1 |
| Wenham, RM | 1 |
| Frasure, H | 1 |
| Eaton, S | 1 |
| Fusco, N | 1 |
| Fu, P | 1 |
| Wright, JJ | 1 |
| Dowlati, A | 1 |
| Waggoner, S | 1 |
| Hainsworth, JD | 1 |
| Thompson, DS | 1 |
| Bismayer, JA | 1 |
| Gian, VG | 1 |
| Merritt, WM | 1 |
| Whorf, RC | 1 |
| Finney, LH | 1 |
| Dudley, BS | 1 |
| Mato, E | 1 |
| Barceló-Batllori, S | 1 |
| Orera, I | 1 |
| Selva, L | 1 |
| Corra, M | 1 |
| González, C | 1 |
| Bell, O | 1 |
| Lerma, E | 1 |
| Moral, A | 1 |
| Pérez, JI | 1 |
| de Leiva, A | 1 |
| Simonelli, M | 1 |
| Zucali, PA | 2 |
| Suter, MB | 1 |
| Lorenzi, E | 1 |
| Rubino, L | 1 |
| Fatuzzo, G | 1 |
| Alloisio, M | 1 |
| Santoro, A | 2 |
| Lee, JM | 1 |
| Sarosy, GA | 1 |
| Annunziata, CM | 2 |
| Azad, N | 1 |
| Minasian, L | 2 |
| Kotz, H | 1 |
| Squires, J | 1 |
| Houston, N | 1 |
| Kohn, EC | 2 |
| Pölcher, M | 1 |
| Eckhardt, M | 1 |
| Coch, C | 1 |
| Wolfgarten, M | 1 |
| Kübler, K | 1 |
| Hartmann, G | 1 |
| Kuhn, W | 1 |
| Rudlowski, C | 1 |
| Bodnar, L | 1 |
| Górnas, M | 1 |
| Szczylik, C | 1 |
| Petrini, I | 1 |
| Meltzer, PS | 1 |
| Luo, J | 1 |
| Lee, C | 1 |
| Lee, HS | 1 |
| Killian, KJ | 1 |
| Wang, Y | 2 |
| Tsokos, M | 1 |
| Roncalli, M | 1 |
| Steinberg, SM | 2 |
| Giaccone, G | 1 |
| Azad, NS | 1 |
| Premkumar, A | 1 |
| Chow, C | 1 |
| Kotz, HL | 1 |
1 review available for niacinamide and Epithelial Neoplasms
| Article | Year |
|---|---|
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase In | 2015 |
5 trials available for niacinamide and Epithelial Neoplasms
| Article | Year |
|---|---|
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2014 |
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Early T | 2010 |
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ovarian Epithelial; Disease-Free Survival | 2011 |
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
3 other studies available for niacinamide and Epithelial Neoplasms
| Article | Year |
|---|---|
The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associ | 2015 |
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aniline Compounds; Animals; Apoptosis Regulatory Protein | 2012 |